CSIMarket
 


Ocular Therapeutix Inc   (OCUL)
Other Ticker:  
 
 

OCUL's Revenue Growth by Quarter and Year

Ocular Therapeutix Inc 's Revenue results by quarter and year




OCUL Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 14.80 14.08 12.31
III Quarter September - 15.08 11.97 12.15
II Quarter June - 15.19 12.27 11.72
I Quarter March 14.77 13.37 13.19 7.34
FY   14.77 58.44 51.51 43.52



OCUL Revenue first quarter 2024 Y/Y Growth Comment
Ocular Therapeutix Inc reported Revenue increase of 10.5% year on year in the first quarter 2024, to $ 14.77 millions, this is lower than Ocular Therapeutix Inc 's recent average Revenue surge of 146.61%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Revenue growth. While Ocular Therapeutix Inc ' s Revenue growth of 10.5% ranks overall at the positon no. 1400 in the first quarter 2024.




OCUL Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 5.11 % 14.38 % 67.48 %
III Quarter September - 25.98 % -1.48 % 106.63 %
II Quarter June - 23.8 % 4.69 % 646.5 %
I Quarter March 10.5 % 1.36 % 79.7 % 181.23 %
FY   - 13.45 % 18.36 % 149.97 %

Financial Statements
Ocular Therapeutix Inc 's first quarter 2024 Revenue $ 14.77 millions OCUL's Income Statement
Ocular Therapeutix Inc 's first quarter 2023 Revenue $ 13.37 millions Quarterly OCUL's Income Statement
New: More OCUL's historic Revenue Growth >>


OCUL Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - -1.86 % 17.63 % 1.32 %
III Quarter September - -0.72 % -2.44 % 3.67 %
II Quarter June - 13.61 % -6.97 % 59.67 %
I Quarter March -0.18 % -5.04 % 7.15 % -0.14 %
FY (Year on Year)   - 13.45 % 18.36 % 149.97 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #229
Overall #1400

Revenue Y/Y Growth Statistics
High Average Low
1787.5 % 146.61 % -6.09 %
(Sep 30 2016)   (Mar 31 2018)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #229
Overall #1400
Revenue Y/Y Growth Statistics
High Average Low
1787.5 % 146.61 % -6.09 %
(Sep 30 2016)   (Mar 31 2018)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Ocular Therapeutix Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
274.51 % 18.74 % -39.86 %
(Sep 30 2020)  


OCUL's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Ocular Therapeutix Inc disclosed decrease in Revenue from the previous quarter by -0.18% to $ 14.77 millions, from $ 14.80 millions achived in the previous reporting period.

When you look into recent downturn in the I. Quarter 2024, you must take into consideration, that usually I. Quarter 2024 results occur sluggish in contrast to the fourth quarter, Sara J. Robinson, Major Pharmaceutical Preparations industry veteran from Seattle added.

Within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Revenue quarter on quarter growth. While Ocular Therapeutix Inc 's Revenue growth quarter on quarter, overall rank is 1166.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #160
Overall #1166
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #56
Healthcare Sector #160
Overall #1166
Revenue Q/Q Growth Statistics
High Average Low
274.51 % 18.74 % -39.86 %
(Sep 30 2020)  


OCUL's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Ocular Therapeutix Inc reported decrease in Revenue from the fourth quarter by -0.18% to $ 14.77 millions, from $ 14.80 millions released in the previous reporting period.

When you analyse current downturn in the quarter, you suppose to assume, that frequently I. Quarter Revenue occur weaker then in the quarter before

Within Major Pharmaceutical Preparations industry 55 other companies have achieved higher Revenue quarter on quarter growth. While Ocular Therapeutix Inc 's Revenue growth quarter on quarter, overall rank is 1166.


Ocular Therapeutix Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 59.84 $ 58.44 $ 57.72 $ 54.60 $ 51.68
Y / Y Revenue Growth (TTM) 15.79 % 13.49 % 16.07 % 9.39 % 4.69 %
Year on Year Revenue Growth Overall Ranking # 1117 # 456 # 310 # 385 # 164
Seqeuential Revenue Change (TTM) 2.4 % 1.26 % 5.71 % 5.65 % 0.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 1401 # 1197 # 1440 # 2093 # 1126




Cumulative Revenue growth Comment
Although Ocular Therapeutix Inc 's Annual Revenue growth year on year were below company's average 146.61% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 15.79% year on year, from 13.49% in Dec 31 2023.

In the Healthcare sector 205 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 456 to 1117.

Revenue TTM Q/Q Growth Statistics
High Average Low
1787.5 %
146.61 %
-6.09 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 86
Healthcare Sector # 206
Overall # 1117

Revenue TTM Y/Y Growth Statistics
High Average Low
1787.5 %
146.61 %
-6.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 86
Sector # 229
S&P 500 # 1401
Cumulative Revenue growth Comment
Although Ocular Therapeutix Inc 's Annual Revenue growth year on year were below company's average 146.61% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 15.79% year on year, from 13.49% in Dec 31 2023.

In the Healthcare sector 205 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 456 to 1117.

Revenue TTM Q/Q Growth Statistics
High Average Low
1787.5 %
146.61 %
-6.09 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 86
Healthcare Sector # 206
Overall # 1117

Revenue TTM Y/Y Growth Statistics
High Average Low
1787.5 %
146.61 %
-6.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 86
Sector # 229
S&P 500 # 1401




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
OCUL's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for OCUL's Competitors
Revenue Growth for Ocular Therapeutix Inc 's Suppliers
Revenue Growth for OCUL's Customers

You may also want to know
OCUL's Annual Growth Rates OCUL's Profitability Ratios OCUL's Asset Turnover Ratio OCUL's Dividend Growth
OCUL's Roe OCUL's Valuation Ratios OCUL's Financial Strength Ratios OCUL's Dividend Payout Ratio
OCUL's Roa OCUL's Inventory Turnover Ratio OCUL's Growth Rates OCUL's Dividend Comparisons



Companies with similar Revenue decrease for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Silk Road Medical Inc 18.36%$ 18.365 millions
Atrion Corporation18.36%$ 18.356 millions
Amneal Pharmaceuticals Inc 18.28%$ 18.284 millions
Bionano Genomics Inc 18.26%$ 18.260 millions
Bausch and Lomb Corp18.05%$ 18.045 millions
Irhythm Technologies Inc 18.02%$ 18.019 millions
Medpace Holdings Inc 17.73%$ 17.732 millions
Veracyte Inc 17.50%$ 17.498 millions
Mimedx Group Inc 16.81%$ 16.806 millions
Artivion Inc 16.48%$ 16.481 millions
Warby Parker Inc 15.99%$ 15.986 millions
Novavax inc 15.94%$ 15.941 millions
Atricure Inc 15.80%$ 15.802 millions
Si bone inc 15.77%$ 15.767 millions
Glaukos Corp15.51%$ 15.514 millions
Penumbra Inc15.43%$ 15.434 millions
Catalyst Pharmaceuticals Inc 15.40%$ 15.396 millions
Electromed Inc 14.94%$ 14.940 millions
Volitionrx Limited14.50%$ 14.503 millions
Ensign Group Inc13.91%$ 13.907 millions
Boston Scientific Corporation13.81%$ 13.809 millions
Iradimed Corporation13.72%$ 13.719 millions
Recursion Pharmaceuticals Inc 13.68%$ 13.681 millions
Universal Biosensors Inc 13.44%$ 13.435 millions
Encompass Health Corporation13.41%$ 13.409 millions
Novocure Limited13.36%$ 13.358 millions
Vertex Pharmaceuticals Inc13.30%$ 13.298 millions
Rigel Pharmaceuticals Inc13.29%$ 13.287 millions
Tandem Diabetes Care Inc 13.16%$ 13.159 millions
Axogen inc 12.86%$ 12.857 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com